Please login to the form below

Not currently logged in
Email:
Password:

Ponesimod

This page shows the latest Ponesimod news and features for those working in and with pharma, biotech and healthcare.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod

J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to ... Data from that trial showed that treatment with ponesimod was associated

Latest news

  • J&J’s ponesimiod tops Aubagio in head-to-head MS trial J&J’s ponesimiod tops Aubagio in head-to-head MS trial

    Sets up regulatory filings and possible approval next year. Johnson &Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory ... Ponesimod, a S1P receptor

  • J&J agrees $30bn deal to acquire Actelion J&J agrees $30bn deal to acquire Actelion

    J&J also takes control of Actelion's late-stage pipeline, including multiple sclerosis candidate ponesimod and cadazolid for diarrhoeal disease, and the US group has also taken an option on

  • J&J back in frame to buy Actelion after Sanofi talks break down J&J back in frame to buy Actelion after Sanofi talks break down

    The two new drugs are predicted to bring in combined sales of $4bn-plus by 2020, and Actelion also has some pipeline candidates in which Clozel has great confidence -including ponesimod

  • Resurgent Actelion catches J&J's eye Resurgent Actelion catches J&J's eye

    J&J could also provide resources to bring forward Actelion's well-regarded pipeline of drugs that extends outside its core focus of PAH, including multiple sclerosis candidate ponesimod and cadazolid

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics